Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
AssetAlso Nonavalent HPV study vaccine
Induces protective immunity against nine human papillomavirus types to prevent infection and associated disease.
- Stage
- Phase 3
- Modality
- Vaccine
- Target
- Not known
- 2
- Indications
- 17
- Trials
- 1
- Developer
Indications
2Human papillomavirus infection
Phase 3, Unknown, NCT06207175, clinicaltrials.gov, 15 Oct 2026
Human papilloma virus infection
Phase 2, Completed, NCT05694728, clinicaltrials.gov, 15 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials17
- Evidence for its targets1
- Competitors3
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.